Neuroprotective therapies: Preclinical reproducibility is only part of the problem

The writer of this is the same person who talked on failed neuroprotective drugs. A quote from  Dr. Michael Tymianskis' comment. on the 1000+ failed neuroprotection drugs.
Your doctor should be intimately acquainted with him and get the complete article. How else is your doctor keeping up-to-date?
 http://stm.sciencemag.org/content/7/299/299fs32.abstract?

1. Michael Tymianski¹,²,³,⁴

+ Author Affiliations

1. E-mail: mike.tymianski@uhn.ca

Science Translational Medicine  05 Aug 2015:
Vol. 7, Issue 299, pp. 299fs32
DOI: 10.1126/scitranslmed.aac9412

• Article
• Figures & Data
• Info & Metrics
• eLetters
• PDF

You are currently viewing the abstract.
View Full Text

Log in

Username Enter your Sciencemag.org username.

Password Enter the password that accompanies your username.

Forgot your username or password?

---

• Join/Subscribe
• Purchase Article
• Activate Member Account
• Recommend a subscription to your library
• Help for librarians

Abstract

Among the many unknowns in the translational path to developing drugs for acute stroke, addressing the reproducibility of preclinical data is only one piece of a multifaceted and incomplete puzzle (Llovera et al., this issue).